Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Authors: Christina Claus, Claudia Ferrara, Wei Xu, Johannes Sam, Sabine M. Lang, Franziska Uhlenbrock, R. Albrecht, Sylvia Herter, Ramona Schlenker, Tamara Hüsser, Sarah Diggelmann, John Challier, Ekkehard Mössner, Ralf J. Hosse, Thomas Höfer, Peter Brünker, Catherine Joseph, Jörg Benz, Philippe Ringler, Henning Stahlberg, Matthias E. Lauer, Mario Perro, Stanford Chen, Christine Küttel, Preethi Latha Bhavani Mohan, Valeria Nicolini, Martina Birk, Amandine Ongaro, Christophe Prince, Reto Gianotti, Gregory O. Dugan, Christopher T. Whitlow, Kiran Kumar Solingapuram Sai, David L. Caudell, Armando G. Burgos-Rodríguez, J. Mark Cline, Michael Hettich, Maurizio Ceppi, Anna Maria Giusti, Flavio Crameri, Wouter H. P. Driessen, Peter N. Morcos, Anne Freimoser–Grundschober, Victor Levitsky, Maria Amann, Sandra Grau-Richards, Thomas von Hirschheydt, Stella Tournaviti, Michael Mølhøj, Tanja Fauti, Viola Heinzelmann‐Schwarz, Volker Teichgräber, Sara Colombetti, Marina Bacac, Alfred Zippelius, Christian Klein, Pablo Umaña - Science Translational Medicine 2019 cited by 266

T cells. FAP- and CD19-4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.